The Technical Analyst
Homology Medicines Inc [FIXX]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Homology Medicines Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
0.77% $0.935
America/New_York / 25 mar 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 3.02 mill |
| EPS: | -35.10 |
| P/E: | -0.0300 |
| Earnings Date: | May 09, 2024 |
| SharesOutstanding: | 3.23 mill |
| Avg Daily Volume: | 0.0295 mill |
| RATING 2024-03-25 |
|---|
| C+ |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Sell | |
| Return On Asset: | Neutral | |
| DE: | Sell | |
| P/E: | Sell | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | ||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.0300 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.01x |
| Company: PE -0.0300 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$-0.343 (-136.67%) $-1.277 |
| Date: 2024-03-31 |
| Expected Trading Range (DAY) |
|---|
|
$ 0.0807 - 1.789 ( +/- 91.37%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-03-25 | Alloway Paul | Buy | 23 530 | Common Stock |
| 2024-03-25 | Alloway Paul | Sell | 18 090 | Restricted Stock Units |
| 2024-03-25 | Michaud Charles Jr | Buy | 6 448 | Common Stock |
| 2024-03-25 | Michaud Charles Jr | Sell | 5 360 | Restricted Stock Units |
| 2024-01-01 | Tzianabos Arthur | Buy | 19 140 | Common Stock |
| INSIDER POWER |
|---|
| 36.13 |
| Last 94 transactions |
| Buy: 1 681 707 | Sell: 632 243 |
Forecast:
16:00 - $16.56
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $16.56
Forecast 2: 16:00 - $16.56
Forecast 3: 16:00 - $16.56
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.935 (0.77% ) |
| Volume | 0.401 mill |
| Avg. Vol. | 0.0295 mill |
| % of Avg. Vol | 1 359.29 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For FIXX
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
FIXX
Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing for various genetic disorders. The company's various set of AAVHSCs allows company to target, through a single injection, a range of disease-relevant tissues, including the liver, central nervous system, peripheral nervous system, bone marrow, cardiac and skeletal muscle, and eye. Its lead product candidate is HMI-102, which is in Phase 2 pheNIX clinical trial, a gene therapy for the treatment of phenylketonuria (PKU) in adults. The company also develops HMI-103 for the treatment of PKU in pediatric patients; HMI-202 to treat metachromatic leukodystrophy; and HMI-203 for the treatment of mucopolysaccharidosis type II, as well as HMI-104 for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Homology Medicines, Inc. was incorporated in 2015 and is headquartered in Bedford, Massachusetts.
Latest Press Releases
2024-03-18 16:30:00 - Press Release
Homology Medicines Declares Distribution To Common Stockholders
Bedford, mass., march 18, 2024 (globe newswire) -- homology medicines, inc. (nasdaq: fixx) today announced that it declared a distribution to its common stockholders of record as of the close of business on march 21, 2024 of the right to receive one contingent value right (cvr) for each outstanding share of homology common stock held by such stockholder as of such record date. the payment date for such distribution is expected to be march 27, 2024 (three business days after the expected closing of the merger on march 22, 2024). each cvr represents the non-transferable contractual right to receive certain contingent payments upon the occurrence of certain events within agreed time periods as provided in the merger agreement and agreement governing the cvrs.
2024-02-27 15:29:00 - Press Release
Homology Medicines Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, Llc Investigates Merger Of Homology Medicines, Inc. - Fixx
New orleans--(business wire)--former attorney general of louisiana charles c. foti, jr., esq. and the law firm of kahn swick & foti, llc (“ksf”) are investigating the proposed merger of homology medicines, inc. (nasdaqgs: fixx) with q32 bio inc. under the terms of the proposed transaction, homology shareholders will end up owning approximately 25% of the combined company, subject to possible adjustment. ksf is seeking to determine whether the merger and the process that led to it are adequa.
2024-01-26 23:35:00 - Press Release
Homology Medicines Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, Llc Investigates Merger Of Homology Medicines, Inc. - Fixx
New orleans , jan. 26, 2024 /prnewswire/ -- former attorney general of louisiana charles c. foti, jr., esq.
2024-01-03 16:08:00 - Press Release
Homology Medicines Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
Homology medicines has an initial 180-day period through june 26, 2024 to regain compliance with minimum bid price requirement
2023-11-17 18:15:00 - Press Release
Homology Medicines Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, Llc Investigates Merger Of Homology Medicines, Inc. - Fixx
New orleans--(business wire)--former attorney general of louisiana charles c. foti, jr., esq. and the law firm of kahn swick & foti, llc (“ksf”) are investigating the proposed merger of homology medicines, inc. (nasdaqgs: fixx) with q32 bio inc. under the terms of the proposed transaction, homology shareholders will end up owning approximately 25% of the combined company, subject to possible adjustment. ksf is seeking to determine whether the merger and the process that led to it are adequa.
Latest News
2023-07-28 11:59:31 - PennyStocks
Best Penny Stocks To Buy? 6 To Watch Before Next Week
Penny stocks hold a distinctive charm for many investors. Amidst fluctuating market trends and the occasional downturn, there's often a group of these low-cost stocks surging in value.
2023-07-27 17:34:32 - PennyStocks
Penny Stocks To Buy? 3 To Watch While The Stock Market Is Down
There's something special about penny stocks. Even when the stock market is down, like it is today, you're likely to find at least a handful exploding higher.
2023-05-11 19:02:37 - Zacks Investment Research
Homology Medicines (FIXX) Reports Q1 Loss, Lags Revenue Estimates
Homology Medicines (FIXX) came out with a quarterly loss of $0.50 per share versus the Zacks Consensus Estimate of a loss of $0.55. This compares to loss of $0.20 per share a year ago.
2023-03-09 19:49:03 - Zacks Investment Research
Homology Medicines (FIXX) Reports Q4 Loss, Misses Revenue Estimates
Homology Medicines (FIXX) delivered earnings and revenue surprises of -17.65% and 23.62%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
2022-11-17 12:02:59 - PennyStocks
5 Penny Stocks To Buy According To Analysts, Targets Up To 1,050%
Analysts say these are penny stocks to buy but do you agree? The post 5 Penny Stocks To Buy According To Analysts, Targets Up To 1,050% appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2022-08-15 19:33:10 - Zacks Investment Research
Homology Medicines (FIXX) Reports Q2 Loss, Lags Revenue Estimates
Homology Medicines (FIXX) delivered earnings and revenue surprises of 10.53% and 23.62%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
2022-06-29 08:00:00 - GlobeNewsWire
Homology Medicines to Present at Upcoming Conferences on its Gene Editing and Gene Therapy Programs for PKU
BEDFORD, Mass., June 29, 2022 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today participation and presentations at the following conferences:
2022-05-16 19:33:11 - Zacks Investment Research
Homology Medicines (FIXX) Reports Q1 Loss, Misses Revenue Estimates
Homology Medicines (FIXX) delivered earnings and revenue surprises of 20% and 38.31%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
2022-03-23 18:48:14 - Zacks Investment Research
Homology Medicines (FIXX) Reports Q4 Loss, Misses Revenue Estimates
Homology Medicines (FIXX) delivered earnings and revenue surprises of -1.72% and 19.80%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
2022-03-08 11:17:25 - Zacks Investment Research
Here's Why Homology Medicines (FIXX) Looks Ripe for Bottom Fishing
After losing some value lately, a hammer chart pattern has been formed for Homology Medicines (FIXX), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.